News Features Low Numbers and ‘Anecdata’: Shoddy Research Rode COVID-19’s First Wave Michael O'Riordan January 11, 2021
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020